REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companyâs NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Companyâs mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Companyâs NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Companyâs third-party licensees. Source
No articles found.
Natural Health Trends Corporation (NASDAQ: NHTC) is an international direct-sellin...
Natural Health Trends Corporation (NASDAQ: NHTC...
Mylan is a global pharmaceutical company committed to setting new standards in hea...
Mylan is a global pharmaceutical company commit...
We believe clean and healthy skin, hair and teeth can be achieved with far fewer p...
We believe clean and healthy skin, hair and tee...
Coherus BioSciences is a leading biosimilar company that develops and commercializ...
Coherus BioSciences is a leading biosimilar com...
Veracyte is a leading genomic diagnostics company that is fundamentally improving ...
Veracyte is a leading genomic diagnostics compa...
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel p...
Evogene (NASDAQ, TASE: EVGN) is a leading biote...
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...
Audentes Therapeutics is a leading AAV-based ge...
Join the National Investor Network and get the latest information with your interests in mind.